- Home
- OXSQ vs ALEC Comparison
OXSQ vs ALEC Comparison
Compare OXSQ & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXSQ | ALEC |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | 103 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.9M | 262.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | OXSQ | ALEC |
|---|---|---|
| Price | $1.81 | $2.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | ★ 1.3M | 862.5K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 23.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | $45.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.56 | $0.87 |
| 52 Week High | $2.73 | $3.40 |
Technical Indicators
Market Signals| Indicator | OXSQ | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 59.42 |
| Support Level | $1.79 | $2.30 |
| Resistance Level | $1.95 | $2.53 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 53.12 | 62.50 |
Price Performance
Historical ComparisonAbout OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.